Magenta Therapeutics

OverviewSuggest Edit

Magenta’s mission is to revolutionize stem cell transplant as the treatment for immune and blood diseases. Stem cell transplant is a curative approach for a variety of severe blood cancers but is seldom used outside of cancer due to toxicities associated with the transplant procedure. Recent clinical data show that stem cell transplant can cure patients suffering from sickle cell disease, inherited metabolic disorders and severe autoimmune diseases. By developing safer and more effective therapeutics for conditioning, next generation products for stem cell mobilization and novel therapeutics for stem cell expansion, Magenta’s products will enable more patients to access the curative power of HSCT.
TypePublic
Founded2016
HQCambridge, US
Websitemagentatx.com

Latest Updates

Employees (est.) (Dec 2019)72
Revenue (FY, 2019)$0
Share Price (Oct 2020)$7.3 (-1%)
Cybersecurity ratingAMore

Key People/Management at Magenta Therapeutics

Bastiano Sanna

Bastiano Sanna

COO
Michael Cooke

Michael Cooke

Chief Scientific Officer
Christina Isacson

Christina Isacson

VP and Head of Business Development
Jason Gardner

Jason Gardner

Chief Executive Officer, President and Cofounder
Show more

Magenta Therapeutics Office Locations

Magenta Therapeutics has an office in Cambridge
Cambridge, US (HQ)
100 Technology Square 5th floor
Show all (1)

Magenta Therapeutics Financials and Metrics

Magenta Therapeutics Revenue

USD

Net income (Q2, 2020)

(19.1m)

EBIT (Q2, 2020)

(20.0m)

Market capitalization (16-Oct-2020)

352.7m

Closing stock price (16-Oct-2020)

7.3

Cash (30-Jun-2020)

136.3m
Magenta Therapeutics's current market capitalization is $352.7 m.
Annual
USDFY, 2018FY, 2019

General and administrative expense

18.6m23.8m

R&D expense

41.3m59.2m

Operating expense total

60.0m83.0m
Quarterly
USDQ2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

General and administrative expense

4.3m5.3m5.8m5.9m6.1m7.3m7.4m

R&D expense

9.7m11.4m10.5m13.4m16.5m14.0m12.6m

Operating expense total

14.0m16.7m16.4m19.3m22.6m21.2m20.0m
Annual
USDFY, 2018FY, 2019

Cash

58.3m65.1m

Prepaid Expenses

2.8m4.1m

Current Assets

145.3m149.8m

PP&E

10.2m9.9m
Quarterly
USDQ2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

173.4m159.7m31.2m33.1m85.5m74.9m136.3m

Prepaid Expenses

2.3m3.0m7.8m10.7m4.7m2.7m3.4m

Current Assets

175.9m162.9m135.1m183.0m165.2m133.1m179.9m

PP&E

2.9m8.1m10.6m10.6m10.2m9.5m9.1m
Annual
USDFY, 2018FY, 2019

Net Income

(57.5m)(76.8m)

Depreciation and Amortization

875.0k1.8m

Accounts Payable

2.5m145.0k

Cash From Operating Activities

(41.9m)(57.1m)
Quarterly
USDQ2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(24.8m)(40.8m)(14.8m)(32.5m)(53.5m)(20.0m)(39.1m)

Depreciation and Amortization

307.0k516.0k423.0k875.0k1.4m493.0k988.0k

Accounts Payable

995.0k2.1m(658.0k)(430.0k)(629.0k)1.1m(238.0k)

Cash From Operating Activities

(18.7m)(29.3m)(14.9m)(30.0m)(41.5m)(16.7m)(35.9m)
USDQ2, 2018

Financial Leverage

1 x
Show all financial metrics

Magenta Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

94/100

SecurityScorecard logo

Magenta Therapeutics Online and Social Media Presence

Embed Graph

Magenta Therapeutics News and Updates

Magenta Therapeutics Blogs

Magenta Therapeutics to Participate in Upcoming Healthcare Investor Conferences in August

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 3, 2020-- Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced that the company will participate in the following August investor

Magenta Therapeutics Announces Closing of Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Magenta Therapeutics Announces Closing of Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares Content Import Tue, 06/30/2020 - 08:01 Magenta Therapeutics Announces Closing of Public Offering, Including Full Exercise of Underwriters’ Option to Purc…

Magenta Therapeutics Announces Pricing of Public Offering

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 24, 2020-- Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, announced the pricing of an underwritten public offering of

Magenta Therapeutics Launches Proposed Public Offering

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 24, 2020-- Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, announced that it has commenced an underwritten public offering of

Magenta Therapeutics and Beam Therapeutics Announce Collaboration to Evaluate Targeted Antibody-Drug Conjugate (ADC) MGTA-117 as Conditioning Regimen for Base Editing Therapies

– MGTA-117 conditioning for precise depletion of cells in the bone marrow could potentially increase patients’ benefit from Beam’s base editing therapies for sickle cell disease and beta thalassemia – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 15, 2020-- Magenta Therapeutics (Nasdaq: MGTA) and Beam

Magenta Therapeutics Provides Portfolio Update: Stem Cell Mobilization and Conditioning Programs Prioritized and Advancing Toward Clinical Milestones

Magenta Therapeutics Provides Portfolio Update: Stem Cell Mobilization and Conditioning Programs Prioritized and Advancing Toward Clinical Milestones Content Import Thu, 06/11/2020 - 07:30 Magenta Therapeutics Provides Portfolio Update: Stem Cell Mobilization and Conditioning Programs Prio…
Show more

Magenta Therapeutics Frequently Asked Questions

  • When was Magenta Therapeutics founded?

    Magenta Therapeutics was founded in 2016.

  • Who are Magenta Therapeutics key executives?

    Magenta Therapeutics's key executives are Bastiano Sanna, Michael Cooke and Christina Isacson.

  • How many employees does Magenta Therapeutics have?

    Magenta Therapeutics has 72 employees.

  • Who are Magenta Therapeutics competitors?

    Competitors of Magenta Therapeutics include PacifiCord, EpiVax and Transgene.

  • Where is Magenta Therapeutics headquarters?

    Magenta Therapeutics headquarters is located at 100 Technology Square 5th floor, Cambridge.

  • Where are Magenta Therapeutics offices?

    Magenta Therapeutics has an office in Cambridge.

  • How many offices does Magenta Therapeutics have?

    Magenta Therapeutics has 1 office.